Hansa to cut staff by 20% in bid to streamline operations

Swedish biotech Hansa Biopharma (Nasdaq Stockholm: HNSA) is preparing to reduce its headcount by around one-fifth as part of a restructuring plan aimed at sharpening operational focus and reducing costs.

The proposed layoffs, subject to mandatory consultations with trade unions in Sweden, are expected to generate annual savings of between 40 million and 50 million Swedish kronor ($4.2 million to $5.3 million). The company, headquartered in Lund, said the restructuring will involve notifying the Swedish Public Employment Service and following local labor regulations before final decisions are made.

Renée Aguiar-Lucander, who took over as chief executive earlier this year, framed the restructuring as a necessary move to drive efficiency and strengthen internal systems. “We are confident that these changes are necessary and will position us to more effectively deliver value to shareholders and patients,” she said.